MEMBERS Trust Co Acquires 151 Shares of Gilead Sciences, Inc. (GILD)

MEMBERS Trust Co raised its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 5.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,791 shares of the biopharmaceutical company’s stock after buying an additional 151 shares during the period. MEMBERS Trust Co’s holdings in Gilead Sciences were worth $221,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in GILD. Hudson Canyon Investment Counselors LLC boosted its stake in Gilead Sciences by 8.1% in the second quarter. Hudson Canyon Investment Counselors LLC now owns 21,718 shares of the biopharmaceutical company’s stock valued at $1,812,000 after buying an additional 1,619 shares in the last quarter. Grandfield & Dodd LLC boosted its stake in Gilead Sciences by 8.6% in the second quarter. Grandfield & Dodd LLC now owns 8,561 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 675 shares in the last quarter. Premier Fund Managers Ltd boosted its stake in Gilead Sciences by 19.3% in the second quarter. Premier Fund Managers Ltd now owns 32,200 shares of the biopharmaceutical company’s stock valued at $2,649,000 after buying an additional 5,200 shares in the last quarter. SignalPoint Asset Management LLC boosted its stake in Gilead Sciences by 7.7% in the second quarter. SignalPoint Asset Management LLC now owns 4,212 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 302 shares in the last quarter. Finally, Diligent Investors LLC purchased a new stake in Gilead Sciences during the second quarter valued at about $220,000. Institutional investors own 74.19% of the company’s stock.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at 67.65 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $65.38 and a 12 month high of $103.10. The company has a market capitalization of $88.62 billion, a price-to-earnings ratio of 6.81 and a beta of 1.11. The company’s 50-day moving average is $72.08 and its 200 day moving average is $75.53.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.61 by $0.09. Gilead Sciences had a net margin of 44.43% and a return on equity of 92.36%. The firm had revenue of $7.30 billion for the quarter, compared to analysts’ expectations of $7.16 billion. During the same quarter last year, the company earned $3.32 EPS. The firm’s revenue for the quarter was down 13.9% compared to the same quarter last year. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post $8.88 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 30th. Shareholders of record on Thursday, March 16th will be issued a $0.52 dividend. The ex-dividend date is Tuesday, March 14th. This represents a $2.08 dividend on an annualized basis and a yield of 3.07%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.47. Gilead Sciences’s dividend payout ratio (DPR) is presently 18.91%.

This piece was reported by sleekmoney and is the property of of sleekmoney. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this piece can be accessed at http://sleekmoney.com/members-trust-co-acquires-151-shares-of-gilead-sciences-inc-gild/1659736.html.

GILD has been the topic of several recent analyst reports. Citigroup Inc. increased their target price on shares of Gilead Sciences to $87.00 in a research note on Thursday, January 26th. RBC Capital Markets lowered their target price on shares of Gilead Sciences to $75.00 in a research note on Wednesday, February 8th. Jefferies Group LLC increased their target price on shares of Gilead Sciences from $93.00 to $95.00 and gave the stock a “buy” rating in a research note on Tuesday, October 25th. Cowen and Company set a $120.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, October 23rd. Finally, Piper Jaffray Companies set a $108.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Thursday, October 20th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, fourteen have assigned a buy rating and two have given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $88.94.

In other Gilead Sciences news, Director John W. Madigan sold 105,000 shares of the firm’s stock in a transaction on Friday, November 18th. The stock was sold at an average price of $74.86, for a total value of $7,860,300.00. Following the transaction, the director now owns 121,761 shares in the company, valued at approximately $9,115,028.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,337 shares of the firm’s stock in a transaction on Tuesday, January 3rd. The shares were sold at an average price of $73.59, for a total value of $5,396,869.83. Following the completion of the transaction, the insider now owns 3,204,433 shares in the company, valued at approximately $235,814,224.47. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/members-trust-co-acquires-151-shares-of-gilead-sciences-inc-gild/1659736.html

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *